Medical-device firm C.R. Bard (BCR -2.5%) dips on a mixed Q3, with net profit roughly flat Y/Y...

|About: C. R. Bard, Inc. (BCR)|By:, SA News Editor

Medical-device firm C.R. Bard (BCR -2.5%) dips on a mixed Q3, with net profit roughly flat Y/Y as sales rose less than expected. The company blames the shortfall on a weakness in its U.S. market, where sales fell roughly 1%. Sales were stronger abroad, rising about 3%. Sales in its vascular business, its largest, were down 2.7%, while its urology unit posted a 3.2% rise. The company also announced plans to acquire privately held Neomend, a developer of sprayable surgical sealants and anti-adhesion products, for $140M.